BOSTON • 9-12 SEPTEMBER

Detailed Program

Print PagePrint Page
Sunday, 9 September
 
13:00 – 20:00 Registration
BCEC Level 3, Ballroom Foyer
14:00 – 19:00 Speaker Check-in
BCEC Level 2, Room 251
 
16:30 – 18:30 Opening Session
Chairs: Dan Barouch, Galit Alter, Bruce Walker, and Lindsey Baden
BCEC Level 3, Ballroom East
 
 

Galit Alter and Dan Barouch
Conference Chairs


Thomas M. Menino
Mayor of Boston


Bill Snow
Global HIV Vaccine Enterprise


Paul Farmer
Harvard Medical School


Trevor Mundel
Bill & Melinda Gates Foundation

 
 
18:30 – 20:00 Welcome Reception
BCEC Level 3, Ballroom Foyer

 

Monday, 10 September
 
18:00 Registration
BCEC Level 3, Ballroom Foyer
17:30 Speaker Check-in
BCEC Level 2, Room 251 
 

08:30 – 10:30

Plenary Session 01: HIV Vaccines in the Broader HIV Prevention Landscape

Chairs: Michel Nussenzweig and Dan Barouch

BCEC Level 3, Ballroom East
 

08:30 – 08:45

Welcome

Deval L. Patrick, Governor of Massachusetts

 

 

08:45 – 09:15

Special Lecture An HIV Vaccine: A Critical Component of a Comprehensive HIV Prevention Strategy

A Fauci


PL01.01

09:15 – 09:40

The Current State of Microbicides as Prevention

S Abdool Karim


PL01.02

09:40 – 10:05

Oral PrEP for HIV Prevention: Next Steps

J Baeten


PL01.03

10:05 – 10:30

ART for Prevention of HIV: Glimmers of Success

M Cohen


PL01.04

 

10:30 – 11:00

Tea and Coffee Break

BCEC Level 3, Ballroom Foyer

 

11:00 – 12:30

Oral Abstract Session 01: Animal Models
Chairs: Genoveffa Franchini and Rama Rao Amara
BCEC Level 2, Room 253 ABC
 

11:00 – 11:15

Significant Protection from Infection and AIDS Progression After Gastrointestinal and Oral Vaccinations, Respectively, with a SIV DNA/rMVA Vaccine

A Aldovini, M Manrique, A Cobo-Molinos, P Kozlowski, A Carvlle


OA01.01

11+:15 – 11:30

Antibodies to the Envelope Protein Protect Macaques from SIVmac251 Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial

G Franchini, P Pegu, S Gordon, B Keele, M Doster, Y Guan, G Ferrari, R Pal, MG Ferrari, S Whitney, L Hudacik, E Billings, M Rao, D Montefiori, D Venzon, C Fenizia, J Lifson, D Stablein, J Tartaglia, N Michael, J Kim


OA01.02

11:30 – 11:45

Immune Control of an SIV Challenge by a Heterolgous and Direct Mucosal Vaccination Regimen in Rhesus Monkeys

C Sun, Z Chen, X Tang, Y Zhang, L Feng, Y Du, L Xiao, L Liu, W Zhu, L Chen, L Zhang


OA01.03

11:45 – 12:00

A Recombinant Attenuated Mycobacterium Tuberculosis-SIV Combination Vaccine Is Safe and Immunogenic in Immunocompromised, SIV-infected Infant Macaques

K Jensen, UD Ranganathan, P Kozlowski, K Van Rompay, D Canfield, R Ravindran, I Khan, P Luciw, G Fennelly, M Larsen, K Abel


OA01.04

12:00 – 12:15

MAb PGT121 Protects Against Mucosal SHIV Challenge in Macaques at Concentrations Corresponding to Its Highly Potent In Vitro Neutralization Capacity

B Moldt, EG Rakasz, N Schultz, P Chan-Hui, K Swiderek, DI Watkins, DR Burton, P Poignard


OA01.05

12:15 – 12:30

Epitope Specificity Appears to Be an Important Determinant of In Vivo Killing Ability of Simian Immunodeficiency Virus (SIV)-specific CD8+ T Cells

L Pozzi, A Carville, V Varner, J Sen, D Knipe, A Kaur


OA01.06

 
11:00 – 12:30 Oral Abstract Session 02: Vaccine Concepts–Protein Immunogens
Chairs: Richard Wyatt and Tim Cardozo
BCEC Level 3, Ballroom East
 
11:00 – 11:15

Identification of a Clade A HIV Envelope Immunogen from Protocol G That Elicits Neutralizing Antibodies to Tier 2 Viruses

S Hoffenberg, S Kosakovsky Pond, A Carpov, D Wagner, A Wilson, R Powell, R Lindsay, H Arendt, J DeStefano, P Poignard, M Simek, S Fling, S Phogat, C Labranche, D Montefiori, D Burton, C Parks, C King, W Koff, M Caulfield


OA02.01

11:15 – 11:30

Prime-boost Regimen Potency and Efficacy with Alphavirus Replicons (SIV Antigen) in Non-human Primates Challenged with Low-dose Intra-rectal SIVsmE860

K Banerjee, S Balsitis, T Jamil, C Jones, A Dey, J Flandez, L Brito, Y Cu, C Beard, S Santra, R Pal, N Miller, NM Valiante, P Mason, SW Barnett, GR Otten


OA02.02

11:30 – 11:45

Minimally Invasive and Surface Electroporation Delivery of DNA Vaccines for the Induction of Robust Humoral Immune Responses Against HIV Antigens

NY Sardesai, AS Khan, J Mc Coy, F Lin, JM Mendoza, M Yang, J Yan, N Hutnick, K Muthumani, DB Weiner, KE Broderick


OA02.03

11:45 – 12:00

Design of Lipid Nanoparticle Delivery Agents for Multivalent Display of Recombinant Env Trimers in HIV Vaccination

S Pejawar-Gaddy, J Kovacs, D Barouch, B Chen, D Irvine


OA02.04

12:00 – 12:15

Eliciting Neutralizing Antibodies with gp120 Outer Domain

Y Qin, DP Han, K Takamoto, MW Cho


OA02.05

12:15 – 12:30

Oral Immunization With a Recombinant Lactococcus Lactis Expressing HIV-1 Gag on the Tip of the Pilus Induces Strong Mucosal Immune Responses

V Chamcha, JR Scott, R Amara


OA02.06 LB

 
11:00 – 12:30 Oral Abstract Session 03: Innate Immunity
Chairs: Alexandra Trkola and Keith Reeves
BCEC Level 2,  Room 258 ABC
 

11:00 – 11:15

SIVΔnef Vaccination Mobilizes Systemic and Mucosal Natural Killer Cells in Mamu A*01+ Macaques

R Reeves, T Evans, J Gillis, M Connole, F Wong, Y Yu, R Johnson


OA03.01

11:15 – 11:30

RV144-like Trial in Macaques Using ALVAC-SIV & gp120, Induces Innate Immunity and Increases the Frequency of NK22 & NKG2A+ Cells in Mucosal Tissues

NP Liyanage, P Pegu, S Gordon, M Cameron, K Foulds, M Doster, M Vaccari, R Koup, M Roederer, R Sékaly, G Franchini


OA03.02

11:30 – 11:45

Adenovirus Vectors from Various Serotypes Induce Distinct Cytokine Profiles

JE Teigler, M Iampietro, DH Barouch


OA03.03

11:45 – 12:00

Infiltration of Dendritic Cells and Antigen Uptake in the Muscle After Injection of HIV-1 Env gp120 in Adjuvant

F Liang, KJ Sandgren, H Fausther-Bovendo, D O'hagan, A Seubert, E De Gregorio, S Rao, N Sullivan, RA Seder, RA Koup, K Loré


OA03.04

12:00 – 12:15

Early Pro-inflammatory Host Response to Recombinant HSV-SIV Vaccination in Sooty Mangabeys

N Rout, S Yu, V Varner, C Kasala-Hallinan, K Rogers, J Sen, D Knipe, F Villinger, A Kaur


OA03.05

12:15 – 12:30

Vaccination with MVA/HIV Induces Differential Recruitment of Monocyte Subsets into the Circulation and Monocyte-specific Transcriptional Programs

E Andersen-Nissen, DE Zak, TR Hensley, DJ Adams, X Hu, A Sato, M Elizaga, PA Goepfert, HL Robinson, A Aderem, MJ McElrath, the NIAID HIV Vaccine Trials Network

OA03.06 LB

 
12:30 – 13:30 Lunch
BCEC Level 2, Rooms 252 AB / 254 AB / 257 AB
 
12:30 – 13:30 Networking Lunch
BCEC Level 2, Room 259 AB
 

 

Join us in BCEC Level 2, Room 259 AB where lunch tables have been reserved for young and early-career investigators and community representatives to network with senior researchers.

 

 
13:30 – 14:45 Oral Abstract Session 04: Mucosal Immunity
Chairs: Daniel Douek and Jo-Ann Passmore
BCEC Level 2,  Room 258 ABC
 

13:30 – 13:45

Immune Complexes Can Dampen Inflammatory Signaling at the Mucosal Surface During Protective SIV Vaccination

AJ Smith, SW Wietgrefe, CS Reilly, PJ Southern, L Duan, KE Perkey, L Shang, R Johnson, AT Haase


OA04.01

13:45 – 14:00

Vaccine-elicited Systemic and Mucosal Humoral Responses of Lactating Rhesus Monkeys Vaccinated with the Transmitted/Founder HIV Envelope 1086C G Fouda, J Amos, AB Wilks, A Chand, D Montefiori, B Haynes, N Letvin, D Pickup, H Liao, SR Permar


OA04.02

14:00 – 14:15

Expanded Memory CD4+ T Cells in the Fetal and the Infant Gut; a Mucosal Route for Mother-to-Child-Transmission of HIV-1

MJ Bunders, C van der Loos, PL Klarenbeek, J van Hamme, J Wilde, N de Vries, RA van Lier, N Kootstra, ST Pals, TW Kuijpers


OA04.03

14:15 – 14:30

Cell Free HIV-1 Virus Can Infect Inner and Outer Foreskin Polarized Explants

MP Lemos, ML Perez, J Sanchez, J Lama, S Montano, J McElrath


OA04.04

14:30 – 14:45

Inflammation in the Male Genital Tract: Implications for HIV Acquisition and Transmission

AJ Olivier, L Roberts, D Coetzee, A Williamson, JS Passmore, WA Burgers


OA04.05

 
13:30 – 14:45 Oral Abstract Session 05: Social/Ethical Issues
Chairs: Barney Graham and Jonathan Fuchs
BCEC Level 2, Room 253 ABC
 

13:30 – 13:45

New Tools to Measure Community and Stakeholder Engagement and Its Impact on Outcomes of Clinical Research

P Bahati, S Hannah, S Seidel, S Aggett, R Siskind, R Campbell, S Williams, A Downie, S Rosas


OA05.01

13:45 – 14:00

An Assessment of Good Participatory Practice Guidelines at HIV Prevention Research Clinical Centers in Eastern and Southern Africa

BP Ngongo, S Hannah, J Mbogua, M Seyoum, M Warren, E Baas, F Priddy


OA05.02

14:00 – 14:15

Social and Ethical Considerations in Engaging American Indian and Alaska Native Communities in HIV Clinical Research

J Velcoff, DL Humes, R Foley, M Ignacio


OA05.03

14:15 – 14:30

Knowledge/Attitude/Practices of HPV & Cervical Cancer, Willingness to Participate in Vaccine Trial in Preparation for HIV & HPV Vaccine Trials in Mali

D Poole, K Tracy, L Levitz, S Yekta, E Kossow, T Huang, M Rochas, K Sangare, K Tounkara, B Aboubacar, O Koita, F Siby Diallo, S Sow, I Téguété, A Dolo, F Bougoudogo, M Lurie, AS De Groot


OA05.04

14:30 – 14:45

Referral and Access to Care of HIV Prevalent Cases; Experience from the Early Capture HIV Cohort Study in Kampala

LN Mutengu, H Kibuuka, M Millard, A Sekiziyivu, S Wakabi, J Nanyondo, G Kawooya, M Robb, N Michael


OA05.05

 
13:30 – 14:45 Oral Abstract Session 06: V1/V2 Antibody Responses
Chairs: Susan Zolla-Pazner and Georgia Tomaras
BCEC Level 3,  Ballroom East
 

13:30 – 13:45

A Short Segment in the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Neutralization Resistance to PG9-like Antibodies

NA Doria-Rose, I Georgiev, RP Staupe, S O'Dell, G Chuang, J Gorman, JS McLellan, M Pancera, M Bonsignori, BF Haynes, DR Burton, WC Koff, PD Kwong, JR Mascola


OA06.01

13:45 – 14:00

Characterization of V1V2-Specific Antibodies Present in Broadly Neutralizing Plasma Isolated from HIV-1 Infected Individuals

C Krachmarov, K Revesz, R Prattipati, C Reichman, Z Lai, W Honnen, B Li, C Derdeyn, A Pinter


OA06.02

14:00 – 14:15

Design of an HIV Env Antigen That Binds with High Affinity to Antibodies Against Linear, Conformational and Broadly Neutralizing Epitopes Within V1/V2

L Liao, M Bonsignori, K Hwang, AM Moody, R Park, S Crawford, H Chen, TL Jeffries, M Cooper, X Lu, R De, N Karasavvas, S Rerks-Ngarm, S Nitayaphan, J Kaewkungwal, S Tovanabutra, P Pitisuttithum, J Tartaglia, F Sinangil, J Kim, NL Michael, GD Tomaras, Z Yang, K Dai, M Pancera, GJ Nabel, JR Mascola, PD Kwong, A Pinter, S Zolla-Pazner9, MS Alam, BF Haynes


OA06.03

14:15 – 14:30

Evidence for Env-V2 Sieve Effect in Breakthrough SIVMAC251Infections in Rhesus Monkeys Vaccinated with Ad26/MVA and MVA/Ad26 Constructs

S Sina, S Tovanabutra, E Sanders-Buell, A Bates, M Bose, S Howell, G Ibitamuno, M Lazzaro, A O'Sullivan, J Lee, T Cervenka, J Kuroiwa, K Baldwin, DH Barouch, M Robb, R O'Connell, NL Michael, JH Kim, M Rolland


OA06.04

14:30 – 14:45

Structural Basis for Germline Gene Usage of a Potent Class of Antibodies Targeting the CD4 Binding Site of HIV-1 gp120

AP West, Jr., R Diskin, MC Nussenzweig, PJ Bjorkman


OA06.05 LB

 
14:45 – 16:00

Poster Session 1 with Tea and Coffee Break

See the inside back cover of the abstract book for the poster presentation schedule.

BCEC Level 3, Ballroom West
 
  Poster Discussion 1a: B Cell Immunology and Antibody Function
Chair: Mattia Bonsignori

BCEC Level 3, Ballroom West

 

15:00 – 15:07

V1/V2-Directed Antibodies Elicited in RV144 Vaccinees Bind to a Structurally Polymorphic Site

JS McLellan, J Gorman, M Bonsignori, K Hwang, H Liao, S Rerks-Ngarm, S Nitayaphan, NL Michael, JH Kim, BF Haynes, PD Kwong


P03.64 LB

15:07 – 15:14

Structural Definition for a New Modality of Broad and Potent Antibody Neutralization at the CD4-binding Site on HIV-1 gp120

T Zhou, S Moquin, R Lynch, X Wu, J Zhu, Y Yang, B Zhang, JR Mascola, PD Kwong


P03.14

15:14 – 15:21

The Breadth of Maternal HIV-1 Specific Neutralizing Antibodies Is Not Associated with a Lower Risk of Mother-to-Infant Transmission

A Chaillon, T Wack, M Braibant, L Mandelbrot, S Blanche, J Warszawski, F Barin


P03.01

15:21 – 15:28

Structural Comparison of Somatically Related PG9 and PG16 in Complex with Their Epitope Reveals Differences in Glycan Recognition

M Pancera, JS McLellan, S Shahzad-ul-Hussan, N Doria-Rose, B Zhang, Y Yang, DR Burton, WC Koff, CA Bewley, PD Kwong


P03.31

15:28 – 15:35

Antibody Subclass Skewing Predicts Enhanced ADCC Activity in Both Natural Infection and Vaccination

A Dugast, A Chung, Y Chang, A Licht, M Ackerman, G Alter


P03.39

15:35 – 15:42

Hyperglycosylated gp120 Mutants Elicit Improved CD4-binding Site Directed Antibodies in a Heterologous Prime:Boost Regimen

FK Ahmed, BE Clark, R Pantophlet


P03.30

 
  Poster Discussion 1b: HIV Transmission and Viral Diversity
Chair: Carolyn Williamson
BCEC Level 3, Ballroom West
 

15:00 – 15:07

Dynamics and Frequency of Gag Transmitted Polymorphisms in Zambia

M Schaefer, J Carlson, D Claiborne, J Prince, W Kilembe, J Tang, P Farmer, R Shapiro, T Ndung'u, J Frater, P Goulder, R Kaslow, S Allen, P Goepfert, D Heckerman, E Hunter


P05.19

15:07 – 15:14

Deep Sequencing Reveals an Association Between HIV-1 Subtype C Mutations in gp41 MPER Epitopes and Mother-to-Child Transmission

L Yin, Y Cai, K Chang, BP Gardner, W Hou, K Nakamura, M Sinkala, C Kankasa, DM Thea, L Kuhn, GM Aldrovandi, MM Goodenow


P05.17

15:14 – 15:21

Postnatally-transmitted HIV-1 Variants Are Efficient at Dendritic Cell Trans-infection and Sensitive to Autologous and Heterologous Neutralization

GG Fouda, T Mahlokozera, K Rizzolo, J Salazar-Gonzalez, M Salazar, G Learn, S Barotra, M Sekaran, E Russell, F Jaeger, F Cai, F Gao, B Hahn, R Swanstrom, S Meshnick, V Mwapasa, L Kalilani, S Fiscus, D Montefiori, B Haynes, J Kwiek, M Alam, S Permar


P05.11

15:21 – 15:28

A New Transmission Map of HIV-1 CRF07_BC in China: Analysis of Sequences from 12 Provinces over a Decade

M Zhefeng, L Jingyun, Z Ping, X Jianqing, Z Xiaoyan


P05.02

15:28 – 15:35

Limited Evidence for Alterations in Gag-mediated HIV Replication Capacity Over the Course of the North American Epidemic (1979-Present)

L Cotton, D Chopera, K Penney, J Carlson, E Martin, A Le, T Kuang, B Walker, J Fuchs, S Buchbinder, T Wagner, M John, S Mallal, B Koblin, K Mayer, A Poon, M Brockman, Z Brumme


P05.20

15:35 – 15:42

Evolutionary Dynamics of HIV-1 Subtype C Accessory and Regulatory Genes in Primary Infection R Rossenkhan, V Novitsky, TK Sebunya, R Musonda, BA Gashe, M Essex

P05.05

 
16:00 – 18:00 Symposium 01: Exploiting the Innate Immune Response
Chairs: Christiane Moog and Galit Alter
BCEC Level 2,  Room 258 ABC
 

16:00 – 16:25

Development of Dendritic Cell-based prophylactic and Therapeutic HIV Vaccine

Y Levy, A Palucka


S01.01

16:25 – 16:50

Adjuvants Influence the Magnitude, Quality and Durability of HIV Env Specific Humoral Immunity in Non-human Primates

JR Francica, G Tomaras, M Alam, G Ferrari, J Mascola, DT O'Hagan, R Seder


S01.02

16:50 – 17:15

Systems Analysis of HIV Vaccine Triggered Innate Immune Responses

D Zak


S01.03

17:15 – 17:40

Profiling Humoral Immunity: Determining Antibody Innate Immune Recruiting Capacity

M Ackerman


S01.04

17:40 – 17:55

Natural Killer (NK) Cell Responses at Female Genital Mucosa to SIV Vaginal Challenge

L Shang, J Duan, A Smith, S Wietgrete, M Zupancic, A Haase


S01.05 OA

 
16:00 – 18:00 Symposium 02: Lessons from Clinical Trials
Chairs: Nina Russell and Lindsey Baden
BCEC Level 2, Room 253 ABC
 

16:00 – 16:25

RV144 Update: Insights from Correlates of Risk, Breakthrough Infections, and Animal Studies in the Context of Future Vaccine Development

J Kim


S02.01

 16:25 – 16:50

Comparative Immunogenicity of HIV Vaccine Candidates in the HVTN

N Frahm, G Tomaras, D Montefiori, P Gilbert, L Corey, JM McElrath


S02.02

16:50 – 17:15

Clinical Studies with Adenovirus 26 Vectored Candidate HIV-1 Vaccines

R Dolin, LR Baden, MS Seaman, DH Barouch


S02.03

17:15 – 17:40

HIV Immunity and Reservoir Following Interventions in Acute HIV Infection: Implication for Functional Cure

J Ananworanich


S02.04

17:40 – 17:55

Vector Induced Skewing of Antibody Fc-Effector Functions

A Chung, A Dugast, H Robinson, Y Chan, ME Ackerman, J Cox, W Koff, D Barouch, S Rerks-Ngarm, N Michael, J Kim, G Alter


S02.05 OA

 
16:00 – 18:00 Symposium 03: New Env Immunogens
Chairs: Joseph Sodroski and Rogier Sanders
BCEC Level 2, Room 253 ABC
 

16:00 – 16:25

Structural basis for HIV-1 Trimeric Env Immunogen

Y Mao


S03.01

16:25 – 16:50

Pure Native Env Trimers on VLP Surfaces and in Soluble Form

JM Binley


S03.02

16:50 – 17:15

Envelope Immunogen: Stable and Homogeneous HIV-1 gp140 Trimers

B Chen


S03.03

17:15 – 17:40

Epitope-focused Vaccines

W Schief


S03.04

17:40 – 17:55

Eliciting Broadly Neutralizing Antibodies Against HIV-1 That Target gp41 MPER

D Han, H Habte, Y Qin, K Takamoto, C LaBranche, D Montefiori, MW Cho


S03.05 OA

 

18:30 – 23:00

Banquet at the Seaport World Trade Center

 

 

 

Just a short 5-minute walk from the hotel you will find the site for our 2012 banquet. All delegates are invited to join us for an outdoor reception offering views of Boston, champagne and a great opportunity to connect with colleagues. The banquet will offer dinner, a dessert buffet and dancing to the best band in Boston, Flipside.

 
Tuesday, 11 September
 
7:30 – 17:30 Speaker Check-in
BCEC Level 2, Room 251
8:00 – 18:00 Registration
BCEC Level 3, Ballroom Foyer
 
 
08:30 – 10:00 Plenary 02: A New Look at the Transmission Event
Chairs: Bruce Walker and Margie McGlynn
BCEC Level 3, Ballroom East
 

08:30 – 09:00

Barriers to Mucosal Transmission: Challenges and Opportunities

JD Estes


PL02.01

09:00 – 09:30

Viral Dynamics and Immune Response in Acute Infection and Their Impact on Viral Set-point

M Robb


PL02.02

09:30 – 10:00

Viral Evolution in Early HIV Infection, and the Implications for Vaccines

B Korber


PL02.03

 
10:00 – 10:30 Tea and Coffee Break
BCEC Level 3, Ballroom Foyer
 
10:30 – 12:30 Oral Abstract Session 07: B Cell Responses
Chairs: Leo Stamatatos and Georgia Tomaras
BCEC Level 3, Ballroom East
 

10:30 – 10:45

Structure-guided Modification and Optimization of Antibody VRC07

Y Kwon, I Georgiev, S O'Dell, W Shi, G Chuang, Y Yang, B Zhang, J Zhu, GJ Nabel, JR Mascola, PD Kwong


OA07.01

10:45 – 11:00

Isolation of a Clonal Lineage of IgA Broadly Neutralizing Antibodies from a Chronically Infected Tanzanian Subject

M Moody, MS Drinker, TC Gurley, JD Amos, JA Eudailey, LC Armand, R Parks, ES Gray, L Morris, A Finzi, X Yang, J Sodroski, H Liao, GD Tomaras, DC Montefiori, BF Haynes


OA07.02

11:00 – 11:15

Deep Sequencing with Longitudinal Sampling of a VRC01-like Antibody Response in a Chronically Infected Individual

Z Zhang, X Wu, N Longo, B Zhang, J Zhu, C Nisc, JC Mullikin, L Wu, GJ Nabel, M Connors, PD Kwong, JR Mascola, L Shapiro


OA07.03

11:15 – 11:30

Antibody Effector Function Is Regulated by a Combination of Adaptive and Innate Signals

A Mahan, K Dionne, J Eusebio, G Alter


OA07.04

11:30 – 11:45

Non-neutralizing IgG Anti-PID Antibodies Decreased Viral Load Following High Dose Vaginal Challenge of Non-human Primates

C Moog, N Dereuddre-Bosquet, M Biedma, S Schmidt, T Decoville, I Mangeot, S Zolla-Pazner, B Vcelar, D Katinger, V Holl, R Le Grand


OA07.05

11:45 – 12:00

Vaccine-induced ADCC-mediating Antibodies Target Unique and Overlapping Envelope Epitopes

J Pollara, M Bonsignori, M Moody, M Alam, H Liao, K Hwang, J Pickeral, J Kappes, C Ochsenbauer, K Soderberg, TC Gurley, DM Kozink, DJ Marshall, JF Whitesides, D Montefiori, JE Robinson, J Kaewkungwal, S Nitayaphan, P Pitisuttithum, S Rerks-Ngarm, J Kim, N Michael, G Tomaras, BF Haynes, G Ferrari


OA07.06

12:00 – 12:15

454 Pyrosequencing and Bioinformatics Analysis of the Lineage of the Broad and Potent gp41-directed Antibody 10e8

G Ofek, J Zhu, Y Yang, B Zhang, K Mckee, M Louder, J Huang, L Laub, M Connors, J Mascola, PD Kwong


OA07.07

12:15 – 12:30

Engineered Mice and B Cell Lines Expressing Broadly Beutralizing Antibodies and Their Unmutated Precursors: Tools for HIV Vaccinology

D Nemazee, C Doyle-Cooper, T Ota, AB Cooper, M Huber, E Falkowska, K Doores, L Hangartner, K Le, D Sok, J Jardine, J Lifson, X Wu, JR Mascola, P Poignard, JM Binley, BK Chakrabarti, WR Schief, RT Wyatt, DR Burton


OA07.08 LB

 
10:30 – 12:30 Oral Abstract Session 08: T Cell Responses
Chairs: Julie McElrath and Julian Schulze zur Wiesch
BCEC Level 2, Room 258 ABC
 

10:30 – 10:45

Cellular Immune Responses and Changes in VL After a Dendritic Cells (DC)-based Therapeutic Vaccine in cART Treated Chronic HIV-infected Patients with CD4 T Cells Above 450/mm

F García, AC Guardo, M Maleno, L Papagno, M Bargalló, N Climent, B Autran, J Gatell, T Gallart, M Plana


OA08.01

10:45 – 11:00

Alterations in Function and Distribution of Regulatory T Cells (Tregs) May Blunt Vaccine Induced Immune Responses in HIV Infection

J van Lunzen, I Toth, P Hartjen, J Schulze zur Wiesch


OA08.02

11:00 – 11:15

Identification of CD8+ T Cell Host Factors Involved in HIV Control

G Gaiha, K McKim, M Woods, M Lichterfeld, A Brass, B Wallker


OA08.03

11:15 – 11:30

PD-1, IL-10, IFN-γ and IL-12 Form a Network to Regulate HIV-1-specific CD4 T Cell and Antigen-presenting Cell Function

F Porichis, L Barblu, DS Kwon, M Hart, J Zupkosky, GJ Freeman, DG Kavanagh, DE Kaufmann


OA08.04

11:30 – 11:45

Distinct Gene Expression Profiles Associated with the Susceptibility of Pathogen-specific CD4+ T Cells to HIV-1 Infection

H Hu, M Nau, P Ehrenberg, A Chenine, Z Daye, Z Wei, N Michael, M Vahey, J Kim, M Marovich, S Ratto-Kim


OA08.05

11:45 – 12:00

HIV Control Through a Single Nucleotide on the HLA-I Locus

H Kløverpris, M Harndahl, J Carlson, A Leslie, M van der Stok, G Huang, F Chen, L Riddell, D Steyn, D Goedhals, C van Vuuren, J Frater, B Walker, T Ndung'u', S Buus, P Goulder


OA08.06

12:00 – 12:15

Accelerated Heterologous Prime-boost Adenovirus Vector-based SIV Vaccine in Neonatal Rhesus Monkeys

J Liu, H Li, M Iampietro, DH Barouch


OA08.07

12:15 – 12:30

Intra-dermal Immunisation with SIV Gag-based Vaccines Alone Inhibits Acquisition of SIVmac251

N Almond, R Stebbings, M Page, B Li, N Berry, C Ham, D Ferguson, N Rose, E Mee, C Stahl-Hennig, G Dickson, T Athanasapoulos, A Benlahrech, S Herath, A Meiser, S Patterson


OA08.08

 
10:30 – 12:30 Oral Abstract Session 09: Clinical Trials
Chairs: Yiming Shao and Sandhya Vasan
BCEC Level 2, Room 253 ABC
 

10:30 – 10:45

Safety and Immunogenicity of a Randomized Phase I Prime-boost Trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 Adjuvanted in Alum or Polyphosphazene

RJ O'Connell, VR Polonis, S Ratto-Kim, J Cox, LL Jagodzinski, J Malia, NL Michael, J Excler, ML Robb, JH Kim


OA09.01

10:45 – 11:00

In Vivo Targeting of HIV Gag to Dendritic Cells in Combination with Poly ICLC Is Safe and Immunogenic in Healthy Volunteers

M Caskey, C Trumpfheller, S Pollak, L Sinnenberg, A Hurley, J Pring, I Shimeliovich, B Yipp, N Anandasabapathy, S Mehandru, P Sarma, R Koup, R Bailer, G Tomaras, A Sato, T Keler, R Steinman, S Schlesinger


OA09.02

11:00 – 11:15

First-in-Human Phase 1 Trial of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 5 HVR48 (rAd5HVR48) HIV-1 Vaccine

SR Walsh, MS Seaman, JA Johnson, RP Tucker, KH Krause, M Weijtens, MG Pau, J Goudsmit, R Dolin, DH Barouch, LR Baden


OA09.03

11:15 – 11:30

Antibody-mediated Inhibition of HIV-1 Elicited by HIV-I DNA Priming and Boosting with Heterologous HIV-1 Recombinant MVA in Healthy Tanzanian Adults A Joachim, C Nilsson, S Aboud, M Bakari, EF Lyamuya, M Robb, M Marovich, C Ochsenbauer, B Wahren, F Mhalu, E Sandström, G Biberfeld, G Ferrari, VR Polonis


OA09.04

11:30 – 11:45

A First-in-Man, Double Blind, Placebo Controlled Study of the Candidate Therapeutic Vaccine Opal-HIV-Gag(c) in HIV Infected Patients Receiving HAART

AG Jackson, HN Kløverpris, A Handley, P Hayes, J Gilmour, M Atkins, B Walker, J Ackland, M Sullivan, P Goulder


OA09.05

11:45 – 12:00

Multiple Antibody Specificities (gp41, V1V2, and V3) Elicited in the Phase II Multiclade (A, B, C) HIV-1 DNA Prime, rAd5 Boost Vaccine Trial

WB Williams, K Jones, A Krambrink, D Grove, P Liu, NL Yates, MA Moody, G Ferrari, J Pollara, Z Moodie, CA Morgan, H Liao, DC Montefiori, C Ochsenbauer, J Kappes, S Hammer, J Mascola, R Koup, L Corey, G Nabel, P Gilbert, G Churchyard, M Keefer, BS Graham, BF Haynes, GD Tomaras


OA09.06 LB

12:00 – 12:15

rAd5 Prime/NYVAC-B Boost Regimen is Superior to NYVAC-B Prime/rAd5 Boost Regimen for Both Response Rates and Magnitude of CD4 and CD8 T-cell Responses

P Bart, Y Huang, N Frahm, S Karuna, M Allen, NK Kochar, S Chappuis, J Gaillard, B Graham, G Pantaleo


OA9.07 LB

12:15 – 12:30

Phase 2a Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Virus Vaccines Expressing Virus-like Particles

P Goepfert, M Elizaga, D Montefiori, J Hural, S DeRosa, G Tomaras, K Seaton, A Sato, L Ouedraogo, Y Donastorg, M Cardinali, J Lama, L Baden, M Keefer, J McElrath, S Kalams, H Robinson


OA09.08 LB

 
12:30 – 13:30 Lunch
BCEC Level 2, Rooms 252 AB / 254 AB / 257 AB
 
12:30 – 13:30 Networking Lunch
BCEC Level 2, Room 259 AB
 

 

Join us in BCEC Level 2, Room 259 AB where lunch tables have been reserved for young and early-career investigators and community representatives to network with senior researchers.

 

 
13:30 – 14:45 Oral Abstract Session 10: HIV Transmission / Diversity
Chairs: Bette Korber and Zabrina Brumme
BCEC Level 2, Room 258 ABC
 

13:30 – 13:45

Impact of Transmitted CTL Escape Mutations on Replicative Capacity and HIV Pathogenesis in Early Infection

J Prince, D Claiborne, D Heckerman, J Carlson, H Prentice, M Schaefer, L Yue, J Mulenga, J Tang, P Goepfert, P Farmer, R Kaslow, S Allen, E Hunter


OA10.01

13:45 – 14:00

A Deeper View of Transmitted/Founder Viruses Using 454 Whole Genome Deep Sequencing

DC Tully, KA Power, H Bedard, CL Boutwell, P Charlebois, EM Ryan, NJ Lennon, M Altfeld, MR Henn, TM Allen


OA10.02

14:00 – 14:15

Modeling Virus Exposure During Male to Female Transmission of HIV-1

A Carias, M McRaven, M Anderson, RS Veazey, TJ Hope


OA10.03

14:15 – 14:30

Beneficial HLA-mediated Viral Polymorphisms on the Transmitted Virus Additively Influence Disease Progression in HIV-1, Subtype C Infection

RS Ntale, DR Chopera, NK Ngandu, M Abrahams, A Debra, M Mlotswa, L Werner, Z Woodman, K Mlisana, S Abdool Karim, CM Gray, C Williamson, CAPRISA 002 AI Study Team


OA10.04

14:30 – 14:45

T-cell Based Sieve Analysis Ties HLA A*02 to Vaccine Efficacy and IgA-C1 Immune Correlate in RV144 Thai Trial

T Hertz, A Gartland, H Janes, S Li, Y Fong, GD Tomaras, D Morris, D Geraghty, GH Kijak, PT Edlefsen, M Rolland, BB Larsen, S Tovanabutra, E Sanders-Buell, AC DeCamp, CA Magaret, H Ahmed, S Nariya, K Wong, H Zhao, W Deng, BS Maust, M Bose, S Howell, M Lazzaro, A Bates, E Lei, A Bradfield, G Ibitamuno, V Assawadarachai, RJ O'Connel, MS deSouza, S Nitayaphan, S Rerks-Ngarm, ML Robb, MJ McElrath, BF Haynes, NL Michael, PB Gilbert, JI Mullins, JH Kim


OA10.05 LB

 
13:30 – 14:45

Oral Abstract Session 11: Vaccine Immunogens / Delivery

Chairs: Harriet Robinson and Sallie Permar

BCEC Level 3,  Ballroom East
 

13:30 – 13:45

HIV-1 Envelope Trimer Elicits Higher Neutralizing Antibody Responses Than Monomeric gp120

JM Kovacs, JP Nkolola, H Peng, A Cheung, J Perry, CA Miller, MS Seaman, D Barouch, B Chen


OA11.01

13:45 – 14:00

Shaping Humoral Responses Against Mini-libraries of HIV Env Antigens via Lipid Nanoparticle Vaccine Delivery

MC Hanson, J Mata-Fink, W Abraham, KD Wittrup, DJ Irvine


OA11.02

14:00 – 14:15

Vaccine Responses to Conserved Regions of the HIV-1 Proteome Are Associated with an Increased Capacity to Inhibit Multiple Virus Isolates Ex Vivo

A Ashraf, J Kopycinski, H Cheeseman, F Lala, J Czyzewska-Khan, A Spentzou, DK Gill, M Keefer, J Excler, P Fast, P Hayes, JH Cox, J Gilmour


OA11.03

14:15 – 14:30

Antigen-specific T Lymphocyte Responses Elicited by a DNA – MVA HIV CN54gp140 Immunization Regime Are Significantly Altered by the TLR4 Adjuvant GLA PF McKay, AV Cope, J Swales, S Joseph, M Esteban, R Tatoud, D Carter, J Weber, RJ Shattock


OA11.04

14:30 – 14:45

Quality of T-cell Responses Versus Reduction in Viral Load: Results from an Exploratory Phase II Clinical Study of Vacc-4x, a Therapeutic HIV Vaccine

K Ellefsen-Lavoie, J Rockstroh, R Pollard, G Pantaleo, D Podzamczer, D Asmuth, J van Lunzen, K Arastéh, D Schürmann, B Peters, B Clotet, D Hardy, A Lazzarin, J Gatell, MA Sommerfelt, I Baksaas, V Wendel-Hansen, B Sørensen


OA11.05 LB

 
13:30 – 14:45

Oral Abstract Session 12: Vaccine Concepts – Vectors and Inserts
Chairs: Punnee Pitisuttithum and Karin Lore

BCEC Level 2, Room 253 ABC
 

13:30 – 13:45

DNA Vaccines Expressing Conserved Elements Provide Potent and Broad Immune Responses

GN Pavlakis, V Kulkarni, A Valentin, M Rosati, NY Sardesai, B Mothe, C Brander, S LeGall, DB Weiner, M Rolland, JI Mullins, BK Felber


OA12.01

13:45 – 14:00

Reinventing the Nucleic Acid Vaccine with Self-amplifying RNA

AJ Geall, GR Otten, A Hekele, W Bogers, H Oostermeijer, P Mooij, K Gerrit, E Verschoor, K Banerjee, Y Cu, CW Beard, LA Brito, JB Ulmer, CW Mandl, SW Barnett


OA12.02

14:00 – 14:15

Adenovirus Serotype 26 Utilizes CD46 as Primary Cellular Receptor and Only Transiently Activates T Lymphocytes Following Vaccination of Rhesus Monkeys

H Li, EG Rhee, K Masek-Hammerman, JE Teigler, P Abbink, DH Barouch


OA12.03

14:15 – 14:30

Full-length HIV-1 Immunogens Induce Greater T Lymphocyte Responses to Conserved Epitopes Than Conserved-Region-Only HIV-1 Immunogens in Monkeys

KE Stephenson, A SanMiguel, NL Simmons, K Smith, JJ Szinger, BT Korber, DH Barouch


OA12.04

14:30 – 14:45

Rational Immunogen Design to Target Specific Germline B Cell Receptors

J Jardine, O Kalyuzhniy, T Ota, A McGuire, S Menis, J Julien, E Falkowska, S MacPherson, M Jones, DR Burton, IA Wilson, L Stamatatos, D Nemazee, WR Schief


OA12.05 LB

 
14:45 – 16:00

Poster Session 2 with Tea and Coffee Break

See inside back cover of the abstract book for the poster presentation schedule.

BCEC Level 3, Ballroom West
 
  Poster Discussion 2a: Innate Immunity
Chair: Dan Zak
BCEC Level 3, Ballroom West
 

15:00 – 15:07

HLA-Cw*0102-Restricted HIV-1 p24 Epitope Variants Can Modulate the Binding of the Inhibitory KIR2DL2 Receptor and Primary NK Cell Function

C Koerner, L Fadda, S Kumar, N van Teijlingen, A Piechocka-Trocha, M Carrington, M Altfeld


P07.09

15:07 – 15:14

Frequent and Strong Antibody-mediated NK Cell Activation to HIV-1 Env in Individuals with Chronic HIV-1 Infection

C Thobakgale, L Fadda, K Lane, I Toth, F Pereyra, S Bazner, T Ndung'u, BD Walker, E Rosenberg, G Alter, M Carrington, T Allen, M Altfeld


P07.03

15:14 – 15:21

HIV Triggers Immunoregulatory Dendritic Cells And Regulatory T Cells Through The Non-canonical NF-kB Pathway

O Manches, MV Fernandez, J Plumas, L Chaperot, N Bhardwaj


P07.16 LB

15:21 – 15:28

Biodistribution of Neutralizing Monoclonal Antibodies IgG1 b12 and LALA in Mucosal and Lymphatic Tissues of Rhesus Macaques

AJ Hessell, E Epson, B Moldt, E Rakasz, S Pandey, WF Sutton, Z Brower, VM Hirsch, DR Burton, NL Haigwood


P08.17

15:28 – 15:35

Critical Role for Monocytes in Mediating HIV-specific Antibody-dependent Cellular Cytotoxicity

M Kramski, GF Lichtfuss, A Schorcht, AP Johnston, R De Rose, R Center, A Jawarowski, S Kent


P03.08

15:35 – 15:42

KIR/HLA Genotype Combinations Are Determinants of Natural Killer (NK) Cell Mediated Antibody-dependent Cellular Cytotoxicity (ADCC) Potency

MS Parsons, P Zanoni, B Tallon, S Miconiatis, N Shoukry, J Bruneau, CM Tsoukas, NF Bernard


P07.19 LB

 
15:35 – 15:42 Poster Discussion 2b:
Clinical and Pre-Clinical Vaccine Trials
Chair: Kathryn Stephenson
BCEC Level 3, Ballroom West
 

15:00 – 15:07

Rapid Development Of Cross-clade Neutralizing Antibody Responses AfterClade B Gp120/Gp140 Protein Priming And Clade CGp140 Protein Boosting 

P Spearman, G Tomaras, D Montefiori, Y Huang, H Ahmed, M Elizaga, J Hural, J McElrath, L Ouedraogo, M Pensiero, C Butler, S Kalams, ET Overton, S Barnett, N Group

 

P04.30 LB

 

 

 

15:07 – 15:14

Uptake and Tolerability of Repeated Mucosal Specimen Collection in Two
Phase 1 AIDS Preventive Vaccine Trials in Kenya
G Mutua, G Omosa-Manyonyi, H Park, P Bergin, D Laufer, PN Amornkul, J Lehrman, P Fast, J Gilmour, O Anzala, B Farah

P04.15

15:14 – 15:21

Immunogenicity of a Universal HIV-1 Vaccine Vectored by DNA, MVA and CHADV-63 in a Phase I/IIA Clinical Trial
NJ Borthwick, T Ahmed, A Rose, U Ebrahimsa, A Black, E Hayton, H Yang, G Hancock, S Campion, N Frahm, S Colloca, A Nicosia, A McMichael,L Dorrell, T Hanke


P04.11

15:21 – 15:28

A Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Replication-defective HIV-1 Vaccine-HIVAX
F Tung, J Tung, M Fischl


P04.20

15:28 – 15:35

Priming with a "Simplified Regimen" of HIV-1 DNA Vaccine Is as Good as a "Standard Regimen" When Boosted with Heterologous HIV-1 MVA Vaccine
P Munseri, A Kroidl, C Nilsson, C Moshiro, S Aboud, A Joachim, C Geldmacher, E Aris, D Buma, E Lyamuya, F Gotch, K Godoy-Ramirez, K Pallangyo, L Maboko, M Marovich, M Robb, M Hoelscher, M Janabi, P Mann, S Joseph, S Mfinanga, W Stoehr, F Mhalu, B Wahren, G Biberfeld, S McCormack, E Sandstrom, M Bakari


P04.01

15:35 – 15:42

Increased Mucosal CD4+ T-cell Activation Following Vaccination with an Adenoviral Vector in Rhesus Macaques
I Bukh, R Calcedo, S Roy, DG Carnathan, R Grant, SJ Ratcliffe, JM Wilson, MR Betts


P11.25

 
16:00 – 18:00 Symposium 04: Cross-cutting Issues in Clinical Trial Design
Chairs: Margaret McCluskey and Chidi Nweneka
BCEC Level 2,  253 ABC
 

16:00 – 16:15

PrEP and Vaccines: When and How to Respond to Positive Data

M Warren


S04.01

16:15 - 16:30

Evolving Standards of Prevention and Implications for Future Trials

DR Wassenaar


S04.02

16:30 - 16:45

Combination Prevention: Scaling Up Delivery While Accelerating Discovery, Lessons From Medical Male Circumcision in Kenya

K Agot, E Omanga


S04.03

16:45 - 17:00

Combination Prevention: Designing and Implementing a New Era of Trials

RV Barnabas


S04.04

17:00 – 17:15

Combination Prevention: A Community Perspective on Complex Trial Results and Designs

M Rose


S04.05

17:15 – 18:00

Moderated Panel Discussion

 

 

16:00 – 18:00

Symposium 05: Mucosal Immunology
Chairs: Francoise Barré-Sinoussi and Doug Kwon

BCEC Level 2, Room 258 ABC

 

16:00 – 16:25

Vaccine-microbicide Combination Studies in a Rhesus Macaque Vaginal Transmission Model

P Moore

S05.01

16:25 – 16:50

Genital Tract Inflammation and Susceptibility to HIV Infection in Women from the CAPRISA 004 Microbicide Trial of Tenofovir Gel

JS Passmore, L Masson, L Werner, S Karim


S05.02

16:50 – 17:15

The Current State of Mucosal Immunity Elicited by Vaccines

R Shattock


S05.03

17:15 – 17:40

Persistence Pays Off: Stringent Control and Potential Clearance of AIDS Virus Infection by Persistent Vaccine-induced Effector Memory T Cells

L Picker


S05.04

17:40 – 17:55

HIV Interactions and the Perils of Epithelial Thinning in the Female Reproductive Tract

A Carias, M McRaven, M Anderson, T Henning, E Kersh, J Smith, K Butler, S Vishwanathan, JM McNicholl, RM Hendry, R Veazey, T Hope


S05.05 OA

 

16:00 – 18:00

Symposium 06: Preclinical Studies and Vaccine Platforms
Chairs: Nelson Michael and Bonaventura Clotet

BCEC Level 3,  Ballroom East

 

16:00 – 16:25

Novel HIV Vaccine Strategies

JC Sadoff, H Schuitmaker, L Baden, L Digilio, M Grazia Pau, M Marovitch, M Robb, N Michael, J Goudsmit, D Barouch, R Dolin


S06.01

16:25 – 16:50

Poxvirus-based Vectors as Immunization Vehicle: Past, Present and Future

J Tartaglia


S06.02

16:50 – 17:15

Pre-clinical Studies and Vaccine Platforms using Chimp Adenovirus Vectors

T Hanke


S06.03

17:15 – 17:40

Passive Immunization for HIV Prevention

F McCutchan, F Randazzo


S06.04

17:40 – 17:55

E-DNA IM or ID Delivery Prime Enhances Antibody and T cell Responses Following Recombinant gp120 Env Boost

NA Hutnick, M Karuppiah, J Pollara, J Yan, DJ Myles, K Broderick, M Morrow, N Sardasai, D Montefiori, S Barnett, G Ferrari, DB Weiner


S06.05 OA

 
 

18:00 – 20:00

Poster Session 3 and Reception

See inside back cover of abstract book for the poster presentation schedule.

BCEC Level 3, Ballroom West
 
  Poster Discussion 3a: T Cell Immunity
Chair: Zaza Ndhlovu
BCEC Level 3, Ballroom West
 

18:30 – 18:37

Different Memory T Cell Phenotypes Are Elicited by Ad5 and Rare Adenoviruses

P Penaloza, E Borducchi, A McNally, N Simmons, J Teigler, N Provine, W Tan, R Ahmed, DH Barouch


P11.04

18:37 – 18:44

A High-dimensional Immune Monitoring Model of HIV-1-specific CD8 T Cell Responses Accurately Identifies Subjects Achieving Spontaneous Viral Control

ZM Ndhlovu, L Chibnik, J Proudfoot, S Vine, A McMullen, K Cesa, F Porichis, D Alvino, A Piechocka-Trocha, P De Jager, BD Walker, D Kaufmann


P11.38

18:44 – 18:51

Maturation of Protective Immunity Induced by SIV∆nef Correlates with Differential Expression of Transcription Factors in SIV-specific CD8+ T Cells

JM Billingsley, PA Rajakumar, NC Salisch, YV Kuzmichev, HS Hong, MA Connole, RK Reeves, H Kang, W Li, RP Johnson


P02.10

18:51 – 18:58

Preferential Targeting Of Co-evolving Gag Residues in Long-term Non Progressors

J Sunshine, K Shekhar, D Heckerman, AK Chakraborty, N Frahm


P11.36

18:58 – 19:05

Early Changes in the CD8 T Cell Immunodominance Hierarchy in Primary HIV Infection Prior to Seroconversion

N Keane, C Almeida, A Chopra, D Cooper, E Demaine, S Mallal, M John


P11.02

19:05 – 19:12

The Early Th17/Treg Ratio Predicts The Immune Activation Set Point In Patients With Primary HIV Infection

MF Chevalier, G Petitjean, C Didier, P Girard, L Meyer, F Barré-Sinoussi, D Scott-Algara, L Weiss


P11.43 LB

 
  Poster Discussion 3b:
Vaccine Concepts and Design
Chair: Eric Sandström
BCEC Level 3, Ballroom West
 

18:30 – 18:37

Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells Using APRIL Improves Antibody Responses
M Melchers, I Bontjer, T Tong, N Chung, P Klasse, D Eggink, M Gentile, A Cerutti, D Montefiori, W Olson, B Berkhout, J Binley, J Moore, R Sanders


P12.11

18:37 – 18:44

Extensive Glycoform Heterogeneity in the gp120 Envelope Proteins Used in the RV144 Trial
B Yu, JF Morales, SM O'Rourke, GP Tatsuno, PW Berman


P12.07

18:44 – 18:51

Native Envelope-based Immunogens Derived from Critical Timepoints in the Development of Breadth Elicit Rapid Neutralizing Antibodies in Rabbits
DC Malherbe, AJ Hessell, ND Sather, B Guo, S Pandey, F Pissani, H Robins, S Kalams, L Stamatatos, NL Haigwood


P12.56

18:51 – 18:58

A Minimal T-cell Immunogen Designed to Cover HIV-1 Specificities Associated with Control Is Immunogenic in Mice and Breaks CTL Immunodominance
B Mothe, A Llano, M Rosati, S Perez-Alvarez, V Kulkarni, B Chowdhury, C Alicea, RK Beach, NY Sardesai, GN Pavlakis, BK Felber, C Brander


P12.16

18:58 – 19:05

Preferential Targeting of Conserved Gag Regions After Vaccination with a Heterologous DNA Prime Modified Vaccinia Ankara Boost HIV Vaccine Regime
A Bauer, L Podola, A Haule, L Sudi, C Nilsson, P Mann, M Missanga, B Kaluwa, L Maboko, C Lueer, M Mwakatima, S Aboud, M Bakari, J Currier, M Robb, S Joseph, S McCormack, E Lyamuya, B Wahren, E Sandström, G Biberfeld, M Hoelscher, A Kroidl, C Geldmacher


P12.41

19:05 – 19:12

CN54gp140: Product Characteristics, Preclinical and Clinical Use - Recombinant Glycoprotein for HIV Immunization
D Katinger, S Jeffs, F Altmann, A Cope, P McKay, N Almond, E Sandström, B Hejdeman, G Biberfeld, C Nilsson, D Hallengärd, B Wahren, T Lehner, M Singh, DJ Lewis, C Lacey, R Shattock


P12.62 LB

 
  Poster Discussion 3a: T Cell Immunity
Chair: Zaza Ndhlovu
BCEC Level 3, Ballroom West
 
Wednesday, 12 September
 
7:30 – 12:30 Speaker Check-in BCEC Level 2, Room 251
8:00 – 14:00 Registration BCEC Level 3, Ballroom Foyer
 
>08:30 – 10:30

Symposium 07: Priming Effective B Cell Responses
Chairs: Lynn Morris and Ralph Pantophlet

BCEC Level 3, Ballroom East

 

08:30 – 08:55

The Unique T Cell Receptor Expressed by Each Naive Helper T Cell Instructs Effector Cell Fate

MK Jenkins


S07.01

08:55 – 09:20

T Follicular Helper Cells in HIV Infection

H Streeck


S07.02

09:20 – 09:45

Evolution of Broadly Cross-neutralizing Antibodies During HIV-1 Infection

PL Moore


S07.03

09:45 – 10:10

Genetic and Structural Basis for Development of High Affinity Antibodies

J Crowe


S07.04

10:10 – 10:25

CD40L Adjuvant for DNA/MVA Vaccine: Enhanced Protection from Acquisition of Neutralization Sensitive & Neutralization Resistant Mucosal SIV Infections

S Kwa, S Sadagopal, J Hong, S Gangadhara, R Basu, L Lai, S Iyer, K Araki, PL Earl, L Wyatt, F Villinger, B Moss, R Ahmed, RR Amara


S07.05 OA

 

08:30 – 10:30

Symposium 08: Therapeutic Vaccination and Strategies for the Cure
Chairs: Janet Siliciano and Xu Yu

BCEC Level 2, Room 253 ABC

 

08:30 – 08:55

Therapeutic Approaches to Curing HIV Infection

S Deeks


S08.01

08:55 – 9:20

Therapeutic Vaccines in Strategies for Functional Cure of HIV

B Autran


S08.02

09:20 – 09:45

Barriers to HIV-1 Eradication

R Siliciano


S08.03

09:45 – 10:10

Persistence of Latently Infected CD4+ T Cells During HAART: Keeping Memory, Keeping HIV

N Chomont


S08.04

10:10 – 10:30

Assembling the Tools to Clear HIV Infection: Contributions from Virology and Immunology

D Margolis


S08.05

 

10:30 – 11:00

Tea and Coffee Break

BCEC Level 3, Ballroom Foyer

 

11:00 – 12:30

Plenary 03: New Concepts in Immune Induction

Chairs: Larry Corey and Dennis Burton

BCEC Level 3, Ballroom East

 

11:00 – 11:30

Follicular T Helper Cells in Vaccination and Lentivirus Pathogenesis

RA Koup


PL03.01

11:30 – 12:00

Maturation Pathways of Broad Neutralizing Antibodies: Blueprints for Vaccine Design

B Haynes


PL03.02

12:00 – 12:30

Experimental HIV Vaccines Induce Immunological Memory in Murine and Human NK Cells

S Paust


PL03.03

 

12:30 – 13:30

Rapporteurs
Chairs: Galit Alter and Dan Barouch

BCEC Level 3, Ballroom East

 

12:30 – 12:45

The Target: How Do We Hit the Virus Where it Hurts? Morgane Rolland MHRP, HJF, USA

 

12:45 – 13:00

People: Where Do We Stand with Moving Towards Efficacy Trials?

Magdalena Sobieszczyk

Columbia University, USA


 

13:00 – 13:15

Vaccimmunology: Advances in Our Understanding of Immune Correlates

Julie Boucau

The Ragon Institute of MGH, MIT and Harvard, USA

 

13:15 – 13:30

Animal Models: What Can Our Furry Friends Teach Us?

Nichole Klatt

National Institute of Health, USA

 

 

13:30 – 14:00

Closing Session and Handover

Chairs: Galit Alter and Dan Barouch

BCEC Level 3, Ballroom East

 

13:30 – 13:35

Bill Snow

Global HIV Vaccine Enterprise

 

13:35 – 13:50

Galit Alter and Dan Barouch

2012 Conference Chairs


 

13:50 – 14:00

José Gatell and Bonaventura Clotet

2013 Conference Chairs